Skip to content
Digistain® logo — Digistain ® - AI risk profiling technology for hormone recep...

Digistain®

Digistain ® - AI risk profiling technology for hormone receptor-positive breast cancer.

Founded 2020 United Kingdom United Kingdom 16 employees Seed Total: $125.00K Biotechnology, Health Care +1

General Information

Company Name Digistain®
Founded Year 2020
Location United Kingdom United Kingdom
Employees 16
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Digistain®. To contact Digistain®, visit digistain.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Digistain® compare?

A PDF of Digistain® and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Digistain® soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Digistain®

Digistain is a UK-based startup that specializes in AI risk profiling technology for hormone receptor-positive breast cancer patients. The company's Digistain® is a groundbreaking digital solution for cancer diagnostics, offering dramatically faster gold standard risk scoring analytics at a lower cost. Approved by the UK's Medicines & Healthcare products Regulatory Agency (MHRA), Digistain® provides a patented risk profiling test for hormone receptor-positive breast cancer patients, based on 15 years of research and development led by respected cancer research scientists at Imperial College and Cancer Research UK. The technology offers an easy-to-read report that offers actionable information for both physicians and patients to determine the best course of treatment, including whether cytotoxic therapy is needed in addition to hormone therapy. As of 2020, the startup operates in the Biotechnology and Health Care industries, with its headquarters based in the United Kingdom. The company achieved a significant milestone with its Seed Round investment on 09 September 2021, securing funding from Acacia Venture Capital Partners. This investment reflects the industry's recognition of Digistain® and its potential to transform cancer diagnostics and treatment.

Business keywords: cancer diagnostics, risk profiling, breast cancer, hormone receptor-positive, MHRA approved, infrared scanning, chemotherapy decision support, Imperial College, London-based startup, cancer research

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
Acacia Venture Capital Partners
09 Sep 2021
Pre Seed Round $125.00K 1
Y Combinator
31 Aug 2021

Digistain® Alternatives & Competitors

View All Alternatives
Digistain® vs
Agendia
Agendia United States

MammaPrint® + BluePrint® provides you with actionable insights throughout your patient’s breast canc...

Private Equity
209 employees
Biotechnology, Health Care
Digistain® vs

Pioneering precise cancer diagnostics through advanced sequencing technology and expert-driven resea...

Grant
2-10 employees
Biotechnology, Health Care
Digistain® vs

Simplifying lung cancer detection.

Seed
7 employees
Biotechnology, Health Care

FAQ About Digistain®

Digistain ® - AI risk profiling technology for hormone receptor-positive breast cancer.
Digistain® was founded in 2020.
Digistain® is headquartered in United Kingdom.
Digistain® operates in Biotechnology, Health Care and Medical Devices. Its work centres on cancer diagnostics, risk profiling, breast cancer and hormone receptor-positive.
Digistain® has approximately 16 employees.
Digistain® has completed 2 funding rounds, raising a total of $125.00K. The latest funding stage is Seed.
Top alternatives and competitors to Digistain® include Agendia, Isabl Inc., OncoSwab. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Digistain® and Agendia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Digistain®, https://www.bouncewatch.com/company/digistain, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout